PREDIX ANNOUNCES PRELIMINARY RESULTS FROM TRIAL OF PRX-08066

A A

Predix Pharmaceuticals has completed a Phase Ib clinical trial to study the pharmacodynamics and tolerability of PRX-08066 in 15 adults conditioned to exercise at high altitudes, with elevated pulmonary artery pressures induced by low oxygen levels (hypoxia). Preliminary results from this trial indicate that treatment with PRX-08066 resulted in a statistically significant reduction in systolic pulmonary blood pressure during exercise hypoxia.

The trial explored the effects of PRX-08066 on pulmonary blood pressure during hypoxia challenges in athletic adults who are conditioned to low oxygen pressure environments, such as high altitudes. Because of their conditioning at high altitudes, these volunteers are more able to tolerate increases in pulmonary pressures when challenged with inhalation of hypoxic gas mixtures. Preliminary results show that a reduction in the systolic pulmonary blood pressure during resting hypoxia and during exercise hypoxia was observed with PRX-08066 treatment, at a dose level of 200 mg given orally bid (twice daily).